Patents Assigned to Children's Research Institute
-
Publication number: 20230194545Abstract: The current disclosure provides antibodies that bind to peptides associated with the primary immunodeficiency disorders (PIDD) Wiskott-Aldrich Syndrome (WAS) and X-linked agammaglobulinemia (XLA). The antibodies can be used in peptide immunoaffinity enrichment coupled to selected reaction monitoring mass spectrometry (immuno-SRM) assays for clinical diagnosis and newborn screening of WAS and XLA, among other uses.Type: ApplicationFiled: April 2, 2021Publication date: June 22, 2023Applicant: Seattle Children's Hospital d/b/a Seattle Children's Research InstituteInventors: Sihoun Hahn, Christopher Collins, Fan Yi, Remwilyn Dayuha
-
Patent number: 11617887Abstract: Systems and methods for promoting neuroplasticity in a brain of a subject to improve and/or restore neural function are disclosed herein. One such method includes detecting residual movement and/or muscular activity in a limb of the subject, such as a paretic limb. The method further includes generating a stimulation pattern based on the detected movement and/or muscular activity, and stimulating the brain of the subject with the stimulation pattern. It is expected that delivering stimulation based on the detected residual movement and/or muscular activity of the limb will induce neuroplasticity for restoring neural function, such as control of the limb. A second method involves detecting brain signals and delivering contingent stimulation. A third method involves delivering pairs of successive stimulus patterns to two brain sites, controlled either by preprogrammed sequences or contingent on neural or muscular activity or movement.Type: GrantFiled: April 19, 2019Date of Patent: April 4, 2023Assignee: University of Washington and Seattle Children's Hospital Children's Research InstituteInventors: Rajesh P. N. Rao, Jeffrey G. Ojemann, Eberhard E. Fetz, Chet T. Moritz, Jeffrey Herron
-
Publication number: 20230050022Abstract: Described herein are aptamers that bind to the transferrin receptor (e.g., CD71) and can be used, in part, for depleting transferrin receptor-expressing cells from a population of therapeutic cells. These aptamer compositions can be used in methods for isolating and/or enriching cells expressing CD71 or depleting cell populations of cells expressing CD71, including for example, tumor cells. Further provided are methods of using the aptamers or cell populations generated using them in the methods disclosed herein for therapies and/or drug delivery.Type: ApplicationFiled: July 15, 2022Publication date: February 16, 2023Applicants: University of Washington, Seattle Children's Hospital d/b/a Seattle Children's Research InstituteInventors: Suzie Hwang Pun, Nataly Kacherovsky, Emmeline Cheng, Ian Cardle, Michael Jensen
-
Publication number: 20230045390Abstract: The present disclosure provides a method of detecting the presence of a hypnozoite stage of Plasmodium vivax in a liver cell. In addition, the present disclosure provides compositions and methods of detecting the presence of a latent Plasmodium vivax infection in a subject and for treating the subject detected to be infected.Type: ApplicationFiled: July 6, 2022Publication date: February 9, 2023Applicant: Seattle Children's Hospital dba Seattle Children's Research InstituteInventors: Stefan H.I. Kappe, Noah Sather, Gigliola Zanghi, Erika L. Flannery, Hemando Del Portillo, Melisa Gualdron Lopez, Carmen Fernández-Becerra
-
Patent number: 11566081Abstract: The present disclosure provides isolated antibodies that bind to acetaminophen-protein adducts that are useful in the detection and diagnosis of acetaminophen-induced toxicity.Type: GrantFiled: January 10, 2020Date of Patent: January 31, 2023Assignees: BioVentures, LLC, Arkansas Children's Research InstituteInventors: Dean W. Roberts, Laura James, Jack Hinson
-
Publication number: 20230017777Abstract: Provided herein are compositions comprising aptamers that specifically bind monocytes and/or macrophage and methods for their use. These aptamer compositions can be used in methods for isolating and/or enriching monocytes and/or macrophages or depleting cell populations of monocytes and/or macrophages. Further provided are methods of using the aptamers or cell populations generated using them in the methods disclosed herein for therapies and/or drug delivery.Type: ApplicationFiled: June 24, 2022Publication date: January 19, 2023Applicants: University of Washington, Seattle Children's Hospital d/b/a Seattle Children's Research InstituteInventors: Suzie Hwang Pun, Meilyn Sylvestre, Nataly Kacherovsky, Emmeline Cheng, Ian Cardle, Chris Saxby
-
Patent number: 11529380Abstract: The invention relates to allergic disease, to the development of allergic disease in infants, to determining the likelihood of development of allergic disease in infants and to minimizing the likelihood of development of allergic disease in infants.Type: GrantFiled: December 22, 2017Date of Patent: December 20, 2022Assignee: MURDOCH CHILDREN'S RESEARCH INSTITUTE ParkvilleInventors: Peter Vuillermin, Anne-Louise Ponsonby, Mimi Tang
-
Publication number: 20220364123Abstract: The present disclosure provides improved genome editing compositions and methods for editing a human Wiskott-Aldrich syndrome gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of WAS, including but not limited to, an immune system disorder, thrombocytopenia, eczema, X-linked thrombocytopenia (XLT), or X-linked neutropenia (XLN).Type: ApplicationFiled: April 24, 2020Publication date: November 17, 2022Applicant: Seattle Children's Hospital d/b/a Seattle Children's Research InstituteInventors: Joel GAY, Iram F. KHAN, Jasdeep MANN, David J. RAWLINGS, Yupeng WANG
-
Patent number: 11492644Abstract: Expression of exogenous SNAI2, EYA1 and SIX1 genes in a cell, tissue or organ not normally having nephron progenitor activity, induces or re-programs that cell to have or subsequently develop nephron progenitor activity. Nephron progenitors induced 5 by expression of SNAI2, EYA1 and SIX1 may be used for the production of nephron cells and tissues that are useful in treatment of kidney disorders, kidney regeneration, kidney transplantation, bioprinting and nephrotoxocity testing.Type: GrantFiled: May 24, 2018Date of Patent: November 8, 2022Assignees: MURDOCH CHILDRENS RESEARCH INSTITUTE, VANDERBILT UNIVERSITY, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OE VETERANS AFFAIRSInventors: Melissa Little, Jessica Vanslambrouck, Lauren Woodard, Matthew Wilson
-
Publication number: 20220339244Abstract: The present invention relates to the discovery that etanercept reduces the rate of resistance to intravenous gamma globulin (IVIG) in subjects with acute Kawasaki disease (KD). In certain embodiments, the co-administration of etanercept and IVIG more effectively treats acute KD in subjects older than 12 months than IVIG alone. In other embodiments, the co-administration of etanercept and IVIG ameliorates coronary artery dilation in high risk subjects.Type: ApplicationFiled: January 18, 2022Publication date: October 27, 2022Applicant: Seattle Children's Hospital (d/b/a Seattle Children's Research Institute)Inventor: Michael A. Portman
-
Publication number: 20220305215Abstract: A kit for resuscitating a subject, particularly a neonatal patient, is described. In an embodiment, the kit includes a syringe having a tip defining a male Luer taper fitting, and an adaptor defining a first end portion shaped to couple with the male Luer taper fitting and a second end portion shaped to cooperatively couple with an opening of an endotracheal tube.Type: ApplicationFiled: March 25, 2022Publication date: September 29, 2022Applicant: Seattle Children's Hospital d/b/a Seattle Children's Research InstituteInventors: Heather Anne Cruz, Jennifer Janett Cerdena
-
Publication number: 20220298255Abstract: Provided herein are several monoclonal antibodies that activate the adhesion activity of human and mouse E-cadherin, including the amino acid sequences for the CDRs that define the binding domains of each monoclonal antibody. Also described are methods of making these antibodies, as well as biologically functional fragments and derivatives thereof; and methods of using them in the treatment, prevention, and/or amelioration of disease and conditions characterized by disruption of normal cell adhesion and/or cell junctions. Specifically contemplated are methods and compositions for the treatment of cancer metastasis as well as inflammatory conditions (such as inflammatory bowel disease and airway inflammation).Type: ApplicationFiled: May 29, 2020Publication date: September 22, 2022Applicant: Seattle Children's Hospital d/b/a Seattle Children's Research InstituteInventor: Barry M. Gumbiner
-
Publication number: 20220283153Abstract: The disclosure provides a panel of biomarkers that individually or in combination can indicate the presence of sepsis as distinguishable from other non-infection related inflammatory conditions. The disclosed biomarkers and related reagents and kits provide strategies for detecting, treating, and monitoring sepsis in subjects. In aspect, the disclosure provides a method for detecting sepsis, comprising contacting a biological sample obtained from the subject with an affinity reagent that specifically binds to one or more of the disclosed novel biomarkers, and detecting differential expression of the one or more biomarkers by detecting binding of the affinity reagent to the biomarker. The method can incorporate use of additional known biomarkers. The method can further comprise treating a subject determined to have sepsis. In some embodiments, the subject is a human subject less than 20 years old.Type: ApplicationFiled: August 4, 2020Publication date: September 8, 2022Applicant: Seattle Children's Hospital d/b/a Seattle Children's Research InstituteInventors: Thomas D. Yager, Dayle L. Sampson, Silvia Cermelli, Therese Seldon, Krupa Navalkar, Adrian Piliponsky
-
Publication number: 20220168740Abstract: Systems, kits, and related methods of making fecal transplants are described. In an embodiment, the system comprises a sample collector defining a sample collection chamber shaped to collect a fecal sample from fecal matter; a sample processing module defining a sample port shaped to receive the sample collector and comprising: a channel positioned to receive at a proximal end of the channel the fecal sample from the sample collection chamber when the sample collector is received by the sample port; and a capsule fluidically coupled to a distal end of the channel adapted to receive a portion of the fecal sample passed therethrough; and a sample processing unit comprising: a housing defining an opening shaped to receive the sample processing module; and an actuator disposed in the housing and configured to urge the sample from the sample collection chamber through the channel to the capsule.Type: ApplicationFiled: March 20, 2020Publication date: June 2, 2022Applicants: University of Washington, Seattle Children's Hospital d/b/a Seattle Children's Research InstituteInventors: Thomas Lendvay, William DePaolo, Blake Hannaford, Scott Weissman, David Suskind
-
Publication number: 20220152300Abstract: An IV system can include a first flow regulator configured to restrict flow through a tube and a second flow regulator configured to restrict flow through the tube downstream of the first flow regulator. The first flow regulator can compress the tube a fixed amount to set an initial flow rate through the tube, while the second flow regulator includes a user-adjustable mechanical compression device that compresses the tube to a variable degree to fine-tune the flow rate through to a more precise flow rate that is lower than the initial flow rate. The flow regulators can utilize a purely mechanical means such that electricity is not required. Such systems can provide a simple, low-cost, and low-power way to provide precise flow control to patients, especially neonatal patient, in any environment. Systems can also include flow rate monitoring, alerting, and shutoff components.Type: ApplicationFiled: November 17, 2021Publication date: May 19, 2022Applicants: University of Washington, Seattle Children's Hospital d/b/a/ Seattle Children's Research InstituteInventors: Yeonjin Cho, Joshua Daeho Chong, Trixie Chui-Yee Ip, Jan Gabrielle Silva, Gregory Charles Valentine, Krystle Perez, Keyi Zhou
-
Publication number: 20220143106Abstract: Methods of reducing or inhibiting Clostridium infection, treating intestinal dysbiosis associated with Clostridium infection, and preventing Clostridium colonization or Clostridium recolonization in a subject are disclosed. The methods include administering to the subject a whole foods exclusionary diet, such as a diet that excludes grains, sugars other than honey, and milk products other than hard cheeses and yogurt fermented for greater than 24 hours.Type: ApplicationFiled: February 14, 2020Publication date: May 12, 2022Applicant: Seattle Children's Hospital d/b/a Seattle Children's Research InstituteInventor: David Suskind
-
Publication number: 20220125951Abstract: Some embodiments of the methods and compositions provided herein relate to transgenes comprising regulatory elements capable of inducing specific transcription of an operably-linked therapeutic payload in a cell in an in vivo microenvironment. In some embodiments, the regulatory elements are responsive to endogenous stimuli of the microenvironment. In some embodiments, the regulatory elements are response to stimuli from chimeric receptors in the cell.Type: ApplicationFiled: January 30, 2020Publication date: April 28, 2022Applicant: Seattle Children's Hospital (dba Seattle Children's Research Institute)Inventors: Courtney Crane, Jennifer Gardell, Harrison Kikuo Chinn
-
Publication number: 20220120745Abstract: The present disclosure relates to biofragment compositions that comprise bioparticle fragments and at least one heterologous antigen-binding molecule. In some embodiments, the biofragment is typically derived from a larger, intact bioparticle that express the at least one heterologous antigen-binding molecule at the surface, and the biofragment has increased solubility to facilitate assays for antigen detection. The disclosure also relates the related methods of using and making the biofragment compositions, as well as systems and devices implementing the biofragment compositions. In some embodiments, the related methods, systems and devices do not require additional detection reagents, such as animal derived detection antibodies.Type: ApplicationFiled: August 27, 2021Publication date: April 21, 2022Applicants: The University of Queensland, Seattle Children's Hospital dba Seattle Children's Research InstituteInventors: Yadveer Grewal, Gerard A. Cangelosi, Muhammad J.A. Shiddiky, Matt Trau
-
Publication number: 20210370037Abstract: Transcutaneous, ultrasound-mediated methods for administering compound(s) to subject tissue(s) are provided. Examples involve positioning an occluding device in a vessel such that the blockage is adjacent to target tissue; engaging the device to occlude outflow from a region adjacent to the tissue; administering compound(s) to the vessel such that it is substantially retained adjacent to the target tissue; determining the location of the compound and/or a detectable adjunct compound optionally administered with the compound, using diagnostic ultrasound, radiography, or fluorography; administering therapeutic ultrasound energy transcutaneously to mediate delivery of the compound across the vessel wall and into adjacent target tissue.Type: ApplicationFiled: April 26, 2019Publication date: December 2, 2021Applicant: Seattle Children's Hospital D/B/A Seattle Children's Research InstituteInventors: Carol Hsing Miao, Feng Zhang
-
Publication number: 20210353731Abstract: The disclosure relates to doubly attenuated malaria parasites that have had the functionality of LISP2 and PlasMei2 genes interrupted through genetic manipulation. The double attenuated malaria parasites disclosed herein are useful for methods and compositions for stimulating of vertebrate host immune systems because of the complete cessation of lifecycle progression in the late liver stage, while providing a comprehensive antigenic presentation representing wildtype liver stage parasites. The disclosure also relates to the additional blood stage and gametocyte antigens to compositions of genetically attenuated malaria parasites (GAPs) to enhance efficient immune stimulation and prevention of disease and transmission related to the presence of blood stage parasites.Type: ApplicationFiled: February 1, 2021Publication date: November 18, 2021Applicant: SEATTLE CHILDREN'S HOSPITAL DBA SEATTLE CHILDREN'S RESEARCH INSTITUTEInventors: Ashley M. Vaughan, Stefan H.I. Kappe, Dorender A. Dankwa